Table 1 Demographics divided into group A and B and subgroups
From: Ab externo canaloplasty results and efficacy: a retrospective cohort study with a 12-month follow-up
Demographics | n |
No. of patients | 439 |
No. of females patients | 246 |
Age (years) | 72.89 ± 11.99 |
No. of male patients | 193 |
Age (years) | 72.07 ± 12.12 |
Bilateral treatment | 167 |
Unilateral treatment | 268 |
No. of eyes operated total | 602 |
No. of eyes excluded due to intraoperative conversion to other surgery | 18 |
→ Trabeculectomy with ologen and MMC 0.02% | 9 |
→ Trabeculectomy with ologen and MMC 0.02% and Phaco | 7 |
→ Viscocanalostomy | 2 |
No. of studied eyes | 584 |
Group A | n |
Canaloplasty | 262 |
→ Subgroup (Advanced POAG – target IOP ≤ 16 mmHg) | 172 |
• MD – dB | 14.31 ± 3.56 |
• IOP – mmHg | 19.15 ± 6.42 |
• Antiglaucoma agents | 2.71 ± 0.95 |
• DCVA – Snellen | 0.58 ± 0.29 |
→ Subgroup (Moderate POAG – target IOP ≤ 18 mmHg) | 51 |
• MD – dB | 7.31 ± 3.22 |
• IOP – mmHg | 20.66 ± 5.04 |
• Antiglaucoma agents | 2.77 ± 0.94 |
• DCVA – Snellen | 0.79 ± 0.21 |
→ Subgroup (Early POAG – target IOP ≤ 21 mmHg) | 39 |
• MD – dB | 4.22 ± 4.13 |
• IOP – mmHg | 21.25 ± 5.67 |
• Antiglaucoma agents | 2.69 ± 1.21 |
• DCVA – Snellen | 0.64 ± 0.21 |
Group B | n |
Canaloplasty with Phacoemulsification | 322 |
→ Subgroup (Advanced POAG – target IOP ≤ 16 mmHg) | 212 |
• MD – dB | 16.11 ± 4.42 |
• IOP – mmHg | 19.39 ± 7.49 |
• Antiglaucoma agents | 2.70 ± 0.95 |
• DCVA – Snellen | 0.53 ± 0.25 |
→ Subgroup (Moderate POAG – target IOP ≤ 18 mmHg) | 51 |
• MD – dB | 8.01 ± 3.01 |
• IOP – mmHg | 19.54 ± 5.90 |
• Antiglaucoma agents | 2.32 ± 1.02 |
• DCVA – Snellen | 0.56 ± 0.26 |
→ Subgroup (Early POAG – target IOP ≤ 21 mmHg) | 39 |
• MD – dB | 5.06 ± 2.17 |
• IOP – mmHg | 19.42 ± 7.32 |
• Antiglaucoma agents | 2.40 ± 1.06 |
• DCVA – Snellen | 0.55 ± 0.23 |